Built and used inside SMEDTEC, a working regulatory consultancy.

SMEDTEC Intelligence | CE Mark Recognition Made Permanent, MHRA 2030 Strategy, Gen-AI Accountability & More

This fortnight's issue is dominated by two landmark UK developments that will reshape market-access planning for years to come: the Government's confirmation that CE-marked devices will be recognised in Great Britain indefinitely, and the MHRA's publication of its Strategy to 2030 — a blueprint for AI-era, patient-centred regulation. Alongside those headline items, we cover the intensifying debate over generative-AI developer accountability at FDA, a widening Olympus import alert, CDRH's staffing rebuild, two batches of MHRA Field Safety Notices, and the upcoming MedSafetyWeek reporting campaign. Read on for the details your regulatory team needs to act on now.

The fortnight in numbers

37
updates
3
markets
0
deadlines < 60d

By market

UK21
GLOBAL15
CA1

By regulator

MHRA21
INDUSTRY15
Health Canada1

Upcoming deadlines

Competitor approvals · last 30 days

270
new approvals
3
regulators
2
markets

By regulator

FDA 510(k)167
BfArM59
FDA PMA44

By market

US211
Germany59

UK Government Confirms Indefinite Recognition of CE-Marked Medical Devices

MHRA · UK

This is the most consequential UK market-access decision of the year for device manufacturers. By removing the previous sunset cliff-edge on CE mark recognition in Great Britain, the Government eliminates the need to pursue separate UKCA marking purely to maintain GB market access. Regulatory teams should update their UK market-access strategies, PRRC arrangements and technical-file roadmaps accordingly, and confirm with distributors that CE certificates remain the operative approval pathway for the foreseeable future.

Read the source →

MHRA Strategy to 2030: Modernising Regulation for AI and Personalised Medicines

MHRA · UK

The MHRA's 2030 Strategy sets the long-term direction of UK medical device and IVD regulation, with explicit focus on AI-enabled products, personalised medicines and accelerated approvals. For SMEs and consultancies, understanding this roadmap is essential for product-development planning, notified-body/UKCA engagement and anticipating future guidance. The agency has also published a companion 'What it means for you' explainer series — essential reading for device regulatory leads.

Read the source →

MHRA Brings New AI and MedTech Agenda to AdvaMed 2026

MHRA · UK

MHRA leadership used the AdvaMed platform to signal its next phase of MedTech and AI regulation to the US industry — an unusually proactive move that underlines the agency's intent to shape global AI-device norms, not just adopt them. Manufacturers developing AI/ML-enabled devices for both the UK and US markets should monitor emerging bilateral alignment opportunities and engage early with MHRA's AI framework as it crystallises alongside the 2030 Strategy.

Read the source →

Generative AI Developer Accountability: Provider Groups Lobby FDA to Assign Liability to Tech Companies

INDUSTRY · GLOBAL

Healthcare provider organisations are formally pressing FDA to hold generative-AI device developers — not clinicians — accountable for safety and performance failures. If FDA adopts this framing in upcoming draft guidance (flagged as imminent by CDRH's Digital Health Center of Excellence), it will materially affect how manufacturers structure risk management, post-market surveillance and contractual liability for Gen-AI software-as-a-medical-device (SaMD) products across global markets.

Read the source →

FDA Widens Olympus Import Alert and Issues Warning Letter Over Quality System Violations

INDUSTRY · GLOBAL

FDA has broadened its 2025 import action to cover additional Olympus endoscopes and issued a new warning letter citing numerous quality-system failures. This is a timely reminder for SME device manufacturers that FDA's quality-system enforcement posture remains robust — particularly for complex reusable devices. Regulatory teams should review their own QMS documentation, complaint-handling processes and import-compliance status, especially if supplying endoscopic or similarly complex equipment to the US market.

Read the source →

CDRH on Hiring Spree After Significant Staff Losses

INDUSTRY · GLOBAL

CDRH Director Dr. Michelle Tarver has confirmed the device centre is actively filling vacancies after losing substantial numbers of clinical reviewers and AI/digital-health specialists. For manufacturers with pending 510(k), De Novo or PMA submissions, this signals potential continued review timeline variability — particularly for AI-enabled and complex devices. Teams should factor reviewer capacity uncertainty into US launch planning and pre-submission meeting strategies.

Read the source →

MHRA Field Safety Notices: 5–9 October and 12–16 October 2026

MHRA · UK

Two consecutive weeks of Field Safety Notices have been published. Regulatory and post-market surveillance teams should review both batches to identify any devices relevant to their portfolio, assess whether competitor or component-level issues affect their own products, and ensure vigilance reporting obligations and FSCA procedures are current. These weekly FSN digests are a mandatory monitoring touchpoint under EU MDR and UKCA post-market surveillance requirements.

Read the source →

#MedSafetyWeek 2–8 November 2026: Yellow Card Updates and Device Incident Reporting Push

MHRA · UK

MHRA's annual MedSafetyWeek campaign (2–8 November 2026) focuses on side-effect and device-incident reporting, with updates to the Yellow Card website and app. Manufacturers and consultancies should brief their medical-affairs and customer-facing teams on the campaign, reinforce internal adverse-event reporting pathways, and use the visibility period to audit vigilance reporting compliance. Updated Yellow Card functionality may also affect how post-market safety data is captured and submitted.

Read the source →

Get this in your inbox

Built by SMEDTEC OS

The regulatory operating system for the medical device supply chain.

Start free trial →